Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958750 | 0.74 | — | — | |
| SCHEMBL11900157 | 0.71 | KDM4E (0.33) | KDM4EGRNSORT1 | |
| SCHEMBL11900113 | 0.71 | — | — | |
| SCHEMBL217424 | 0.71 | — | — | |
| SCHEMBL378865 | 0.67 | CDK8 (0.37) | KDM4E | |
| SCHEMBL294525 | 0.67 | — | — | |
| SCHEMBL15312633 | 0.65 | — | — | |
| SCHEMBL12265088 | 0.59 | KDM4E (0.35) | KDM4EGRNSORT1 | |
| SCHEMBL440932 | 0.59 | KMT2A (0.41) | KDM4EGRNSORT1 | |
| SCHEMBL25251790 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4362949-A2 | USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING | Lutris Pharma Ltd. (IL) | 2024-05-08 | — | — | EP | claimed |
| US-20240122933-A1 | USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING | LUTRIS PHARMA LTD (IL) | 2024-04-18 | — | — | US | claimed |
| EP-3923911-B1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2023-07-12 | — | — | EP | claimed |
| WO-2023275620-A2 | USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING | LUTRIS PHARMA LTD. (IL) | 2023-01-05 | — | — | WO | claimed |
| EP-3661515-B1 | NOVEL BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2022-02-23 | — | — | EP | claimed |
| CN-111132680-B | Novel BRAF inhibitors and their use for treating skin reactions | 鲁特里斯制药有限公司 | 2022-02-08 | — | — | CN | claimed |
| EP-3923911-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | Lutris Pharma Ltd. (IL) | 2021-12-22 | — | — | EP | claimed |
| US-20210346389-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2021-11-11 | — | — | US | claimed |
| CN-113382717-A | Use of topical BRAF inhibitor compositions for the treatment of radiodermatitis | 鲁特里斯制药有限公司 | 2021-09-10 | — | — | CN | claimed |
| US-10927112-B2 | BRaf inhibitors and use thereof for treatment of cutaneous reactions | LUTRIS PHARMA LTD. (IL) | 2021-02-23 | — | — | US | claimed |
| EP-1129689-A2 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| WO-2001062220-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2001-08-30 | — | — | WO | claimed |
| EP-1066263-A1 | NOVEL CATIONIC 2-ACYLAMINOPHENOLS, THEIR USE AS COUPLER FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM, AND DYEING METHODS | L'OREAL (FR) | 2001-01-10 | — | — | EP | claimed |
| EP-1066264-A2 | NOVEL CATIONIC 2-SULPHONYLAMINOPHENOLS, THEIR USE AS COUPLERS FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM AND DYEING METHODS | L'OREAL (FR) | 2001-01-10 | — | — | EP | claimed |
| EP-1066022-A1 | COMPOSITIONS FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC COUPLER, NOVEL CATIONIC COUPLERS, THEIR USE FOR OXIDATION DYEING AND DYEING METHODS | L'OREAL (FR) | 2001-01-10 | — | — | EP | claimed |
| EP-1066246-A1 | NOVEL CATIONIC COUPLERS AND THEIR USE FOR OXIDATION DYEING | L'OREAL (FR) | 2001-01-10 | — | — | EP | claimed |
| WO-2000042979-A1 | COMPOSITIONS FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC COUPLER, NOVEL CATIONIC COUPLERS, THEIR USE FOR OXIDATION DYEING AND DYEING METHODS | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| WO-2000042971-A2 | NOVEL CATIONIC 2-SULPHONYLAMINOPHENOLS, THEIR USE AS COUPLERS FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM AND DYEING METHODS | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| WO-2000043368-A1 | NOVEL CATIONIC 2-ACYLAMINOPHENOLS, THEIR USE AS COUPLER FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM, AND DYEING METHODS | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| WO-2000043356-A1 | NOVEL CATIONIC COUPLERS AND THEIR USE FOR OXIDATION DYEING | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122933-A1 | USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING | BRAF, NRAS, RAF1 | KDM4E 1801/4885GRN 3055/4885SORT1 3467/4885 |
| US-20210346389-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | BRAF, NRAS, RAF1 | KDM4E 1839/4885GRN 1406/4885SORT1 1944/4885 |
| US-10927112-B2 | BRaf inhibitors and use thereof for treatment of cutaneous reactions | BRAF, NRAS, RAF1 | KDM4E 2450/4885GRN 1865/4885SORT1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.